Characteristic | Entire cohort (n = 132) | CC-CCD, mg/m2 | P valuea | |
---|---|---|---|---|
< 160 (n = 52, %) | ≥ 160 (n = 80, %) | |||
Sex | 0.354 | |||
 Male | 92 (69.7) | 39 (75.0) | 53 (66.2) |  |
 Female | 40 (30.3) | 13 (25.0) | 27 (33.8) |  |
Age, years | 0.494 | |||
 ≤ 15 | 69 (52.3) | 25 (48.1) | 44 (55.0) |  |
 < 15 | 63 (47.7) | 27 (51.9) | 36 (45.0) |  |
Smoking history | 0.170 | |||
 No | 123 (93.2) | 46 (88.5) | 77 (96.2) |  |
 Yes | 9 (6.8) | 6 (11.5) | 3 (3.8) |  |
BMI, m2 | 0.310 | |||
 ≤ 1.45 | 64 (48.5) | 22 (42.3) | 42 (52.5) |  |
 > 1.45 | 68 (51.5) | 30 (57.7) | 38 (47.5) |  |
EBV DNA, copy/mL | 0.293 | |||
 < 4000 | 52 (39.4) | 17 (32.7) | 35 (43.7) |  |
 ≥ 4000 | 80 (60.6) | 35 (67.3) | 45 (56.3) |  |
T stageb | 0.281 | |||
 T1 | 1 (0.8) | 1 (1.9) | 0 (0) |  |
 T2 | 4 (3.0) | 1 (1.9) | 3 (3.8) |  |
 T3 | 59 (44.7) | 27 (51.9) | 32 (40.0) |  |
 T4 | 68 (51.5) | 23 (44.2) | 45 (56.3) |  |
N stageb | 0.165 | |||
 N0 | 1 (0.8) | 1 (1.9) | 0 (0) |  |
 N1 | 18 (13.6) | 8 (15.4) | 10 (12.5) |  |
 N2 | 65 (49.2) | 29 (55.8) | 36 (45.0) |  |
 N3 | 48 (36.4) | 14 (26.9) | 34 (42.5) |  |
Overall stageb | 0.114 | |||
 III | 36 (27.3) | 19 (36.5) | 17 (21.3) |  |
 IVA | 48 (36.4) | 19 (36.5) | 29 (36.2) |  |
 IVB | 48 (36.4) | 14 (26.9) | 34 (42.5) |  |
NAC cycles | 0.062 | |||
 2 | 60 (45.5) | 30 (57.7) | 30 (37.5) |  |
 3 | 66 (50.0) | 21 (40.4) | 45 (56.3) |  |
 4 | 6 (4.5) | 1 (1.9) | 5 (6.2) |  |
NAC regimens | < 0.001 | |||
 TPF | 73 (55.3) | 18 (34.6) | 55 (68.8) |  |
 TP | 20 (15.2) | 13 (25.0) | 7 (8.8) |  |
 PF | 35 (26.5) | 21 (40.4) | 14 (17.5) |  |
 GP | 4 (3.0) | 0 (0.00) | 4 (5.0) |  |
Adjuvant chemotherapy | 0.575 | |||
 No | 129 (97.7) | 50 (96.1) | 79 (98.7) |  |
 Yes | 3 (2.3) | 2 (3.9) | 1 (1.3) |  |
NAC-CCD, mg/m2 | 0.112 | |||
 < 180 | 62 (47.0) | 29 (55.8) | 33 (41.3) |  |
 ≥ 180 | 70 (53.0) | 23 (44.2) | 47 (58.7) |  |
Radiation dose, cGy | 0.386 | |||
 < 6800 | 64 (49.6) | 22 (44.0) | 42 (53.2) |  |
 ≥ 6800 | 65 (50.4) | 28 (56.0) | 37 (46.8) |  |